OxFORD Asset Management LLP Raises Holdings in Masimo Co. (MASI)

OxFORD Asset Management LLP raised its stake in shares of Masimo Co. (NASDAQ:MASI) by 193.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,956 shares of the medical equipment provider’s stock after buying an additional 11,847 shares during the period. OxFORD Asset Management LLP’s holdings in Masimo were worth $1,546,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. WINTON GROUP Ltd bought a new position in shares of Masimo during the 3rd quarter valued at $4,172,000. Schroder Investment Management Group raised its holdings in shares of Masimo by 16.7% during the 3rd quarter. Schroder Investment Management Group now owns 338,115 shares of the medical equipment provider’s stock valued at $28,709,000 after purchasing an additional 48,300 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Masimo by 6.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 851,234 shares of the medical equipment provider’s stock valued at $72,278,000 after purchasing an additional 48,536 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Masimo by 15.6% during the 3rd quarter. Legal & General Group Plc now owns 41,189 shares of the medical equipment provider’s stock valued at $3,560,000 after purchasing an additional 5,566 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its holdings in shares of Masimo by 6.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 32,772 shares of the medical equipment provider’s stock valued at $2,847,000 after purchasing an additional 1,870 shares in the last quarter. 83.74% of the stock is owned by institutional investors.

MASI has been the topic of a number of recent research reports. Stifel Nicolaus restated a “buy” rating and set a $108.00 price target on shares of Masimo in a report on Friday, November 3rd. Zacks Investment Research upgraded shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Thursday, November 2nd. Finally, BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $97.17.

In related news, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the transaction, the director now owns 73,249 shares in the company, valued at approximately $6,592,410. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Yongsam Lee sold 5,900 shares of Masimo stock in a transaction on Friday, December 1st. The stock was sold at an average price of $88.31, for a total transaction of $521,029.00. Following the completion of the transaction, the executive vice president now owns 70,800 shares in the company, valued at approximately $6,252,348. The disclosure for this sale can be found here. Insiders sold a total of 53,074 shares of company stock worth $4,737,245 in the last quarter. Insiders own 16.60% of the company’s stock.

Masimo Co. (NASDAQ:MASI) opened at $86.86 on Monday. The company has a market cap of $4,490.00, a price-to-earnings ratio of 33.28, a P/E/G ratio of 2.93 and a beta of 0.72. Masimo Co. has a twelve month low of $65.16 and a twelve month high of $104.71.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.53 by $0.17. The firm had revenue of $193.69 million for the quarter, compared to the consensus estimate of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The business’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS. equities analysts expect that Masimo Co. will post 2.95 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/18/oxford-asset-management-llp-raises-holdings-in-masimo-co-masi.html.

About Masimo

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply